NIH Research Funding Drops $1B Under Trump Administration

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 18, 2025.

By India Edwards HealthDay Reporter

TUESDAY, Feb. 18, 2025 -- Federal funding for medical research has dropped by roughly $1 billion this year, raising alarm among universities, medical centers and lawmakers who warn the shortfall could slow progress in cancer, diabetes and heart disease research.

The National Institutes of Health's (NIH) grant review process was also disrupted when the Trump administration suddenly canceled scheduled funding meetings due to a temporary communications freeze.

Some of those meetings have since resumed, but experts warn that delays could impede new research projects.

The drop in funding comes amid administrative delays and policy changes under the Trump administration, including a controversial move to cut NIH payments for research facility and administrative costs.

A federal judge in Massachusetts temporarily blocked those cuts, pending upcoming hearings.

The NIH awarded about $2.5 billion in grants in the first six weeks of 2024, federal records show. This year, that number has plummeted to $1.4 billion -- hundreds of millions of dollars lower than the amount awarded in the same timeframe over the past six years.

“The president has completely stopped funding for research that discovers cures for diseases that devastate families across the country, like cancer and Alzheimer’s disease, all so he can give tax breaks to billionaires and big corporations,” U.S. Sen. Tammy Baldwin (D-Wis.), said in a statement.

“Make no mistake, their efforts to rob Peter to pay Paul means crushing families’ hopes and dreams of having cures,” she added.

The NIH typically distributes roughly $36 billion in grants annually. The funding supports groundbreaking research in such areas as gene therapy, immune-based cancer treatments, cystic fibrosis and sickle cell disease.

Without full funding, experts warn that vital projects could be delayed or stopped altogether.

U.S. Sen. Patty Murray (D-Wash.) attempted to restore NIH funding to previously agreed-upon levels through a budget bill, but the effort failed on a party-line vote.

“Trump and Elon -- either through sheer ignorance or a genuine lack of caring -- are putting lifesaving research in America on life support,” Murray said in a statement, referring to billionaire Elon Musk and his reported influence on White House budget decisions.

Musk heads the Trump-created U.S. Department of Government Efficiency, or DOGE, which has slashed funding and staff in several federal departments and agencies.

What's more, the administration has also faced internal turmoil at the NIH, with two high-ranking officials suddenly resigning and the agency still lacking a permanent director.

Meanwhile, Trump's nominee to head the NIH, Stanford professor Dr. Jay Bhattacharya, is preparing for Senate confirmation hearings in the coming weeks.

The uncertainty at the NIH comes as Robert F. Kennedy Jr., the new secretary of health and human services (HHS), has suggested he wants to back off on infectious disease research and focus more on chronic conditions like diabetes and heart disease. NIH is part of Kennedy's department.

The New York Times reported that the proposed cuts in medical research have raised deep concerns among recipient institutions.

“If the federal government cuts its investment, we will have to scale back on research, and cutting-edge science will be cut short,” Dean Madden, the vice provost for research at Dartmouth’s medical school, said at a news conference Friday, according to The New York Times.

“You don’t know what discoveries won’t be made as a result, but they might include a cure for some childhood cancer or treatment for Alzheimer’s or dozens of other diseases that are afflicting patients across our country,” Madden added.

Sources

  • The New York Times, media report, Feb. 14, 2025
  • U.S. Sen. Tammy Baldwin, statement, Feb. 14, 2025: U.S. Sen. Patty Murray, statement, Feb. 15, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-02-19 06:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords